Potential Early Drivers of Disease in Treatment-Naive CLL Identified
Mutated ATM and unmutated IGHV were identified as potential early drivers of disease in treatment-naive patients with chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia News
CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR
Chronic Lymphocytic Leukemia News
Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL
Inferior survival for patients with chronic lymphocytic leukemia who progress with lymphadenopathy.
After Long-Term Ibrutinib Therapy for CLL, BTK Mutations May Signal Progression
Some patients with BTK mutations could benefit from treatment changes at earlier stages.
Pretreatment Growth Patterns of Early-Stage CLL as a Predictor of Disease Course
Results of this study suggest that the clonal and subclonal characteristics of early-stage CLL shape the dynamics of the disease course.
Study Further Characterizes Symptomatic Bronchial Involvement in CLL
Patients with CLL who had symptomatic bronchial involvement had a significantly higher proportion of anomalies in small airways and peripheral bronchi.
Nonrelapse Mortality After CAR-T Therapy Remains High
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
Real-World Treatment Patterns, Adverse Events, and Health Care Costs for Patients With CLL
Interestingly, over two-thirds of patients did not receive active treatment for CLL during the study period.
Venetoclax Plus Obinutuzumab Prevails as First-Line Combo in CLL
Patients with chronic lymphocytic leukemia who received venetoclax plus obinutuzumab had better survival outcomes compared with chemoimmunotherapy.
CAR-T Cell Therapy Liso-Cel Deemed Safe and Active in CLL and SLL
Chimeric antigen receptor T-cell therapy “liso-cel” was deemed safe and clinically active in chronic lymphocytic leukemia and small lymphocytic leukemia.
Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Single-Agent Acalabrutinib Meets Primary End Point of Phase 3 Study in R/R CLL
A phase 3 study of single-agent acalabrutinib versus rituximab plus idelasib or bendamustine in RR/CLL will be closed early due to favorable results at interim analysis.
Tumor Lysis Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax
High risk for tumor lysis syndrome and creatinine clearance below 80 mL/min were associated with tumor lysis syndrome development.
An Integrated Analysis for Selecting Ibrutinib-Based Combination Therapy in CLL
An integrated assessment of the results from 2 assays showed promise for tailoring ibrutinib-based targeted therapy in patients with CLL.
Sustained Efficacy and Safety of Ibrutinib in Relapsed/Refractory CLL
At a follow-up of almost 4 years, over two-thirds of patients randomly assigned to receive ofatumumab crossed over to receive ibrutinib.
Disease Progression Is Associated With Increased Costs for Patients With Hematologic Malignancies
Relative increases in health care costs associated with disease progression were more than 30% in subgroups of patients with CLL and NHL.
Designing a Clinical Trial to Evaluate Multistage Treatment Approaches in CLL
Sequential multiple assignment randomized trials (SMART) have an adaptive design based on patient response to therapy.
Ibrutinib Plus Nivolumab in 4 Cohorts of Patients With R/R NHL or CLL
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
Fixed Duration of Venetoclax-Rituximab for CLL May Prolong Survival
When used as a fixed-duration venetoclax-rituximab combination, 62% of patients achieved an undetectable minimal residual disease level in peripheral blood.
Gly101Val Mutation Directly Causes Resistance to Venetoclax
Researchers identified a single heterozygous nucleotide variant that confers resistance to venetoclax, and it’s a mutation that may be detected years before clinical relapse occurs.
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
